Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has reported new data from two phase II ramucirumab (IMC-1121B) trials, Abstract #1245 and Abstract#1287 in patients with non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
Abstract #1245 studies were designed to study advanced NSCLC chemotherapy-naive patients treated with ramucirumab in combination with first-line ALIMTA (pemetrexed for injection)/platinum-based chemotherapy while Abstract#1287 studied patients treated with ramucirumab in combination with paclitaxel/carboplatinum chemotherapy.
Both the studies supported continued development of ramucirumab in lung cancer.
Lilly Oncology business unit clinical development and medical affairs vice president Richard Gaynor said, "Ramucirumab is one of the key molecules in Lilly’s pipeline and represents one of the largest clinical programs currently underway at Lilly, with six Phase III trials ongoing around the globe including one in lung cancer."
Lilly Oncology product development and medical affairs vice president Richard Gaynor said Lilly is encouraged by the results from two Phase II trials, which indicate that ramucirumab may be beneficial to patients with non-small cell lung cancer.
"These findings support our ongoing evaluation of ramucirumab for lung cancer patients and will need to be confirmed in larger pivotal studies," Gaynor added.